With once-weekly injections, semaglutide gradually accumulates until it reaches steady state (a plateau), typically after about 45 weeks
One of the biggest trends reshaping the pharmacy benefits space today
Research literature describes retatrutide as a multi-receptor agonist acting on GLP-1, GIP, and glucagon pathways, with ongoing investigation into its potential metabolic effects
According to the American Academy of Ophthalmology (AAO), NAION symptoms include: The AAO has highlighted the need for further research into the connection between these medications and NAION, urging patients to be vigilant about any changes in their vision
The FDA added a pancreatitis warning to semaglutide and other GLP-1 drugs years ago
The SHAPE real-world study found 83.5% of semaglutide users reached 2.4 mg versus only 25.9% of tirzepatide users at 15 mg, and outcomes still favored tirzepatide